Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rajasree Golla

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
ACS Medicinal Chemistry Letters|July 23, 2014
Optimization of 1,2,4-Triazolopyridines as Inhibitors of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1)Jun Li, Lawrence J Kennedy, Haixia Wang, et al.
Bioorganic & Medicinal Chemistry Letters|February 13, 2007
Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulatorsLawrence G Hamann, Mark C Manfredi, Chongqing Sun, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2008
Pyridine amides as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1Haixia Wang, Zheming Ruan, James J Li, et al.
Journal of Medicinal Chemistry|April 9, 2009
N-aryl-oxazolidin-2-imine muscle selective androgen receptor modulators enhance potency through pharmacophore reorientationAlexandra A Nirschl, Yan Zou, Stanley R Krystek, et al.
Journal of Medicinal Chemistry|March 18, 2005
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activitiesPratik V Devasthale, Sean Chen, Yoon Jeon, et al.
ACS Medicinal Chemistry Letters|January 8, 2019
Discovery of Clinical Candidate BMS-823778 as an Inhibitor of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1)Jun Li, Lawrence J Kennedy, Steven J Walker, et al.
Bioorganic & Medicinal Chemistry Letters|October 11, 2011
Discovery of 3-hydroxy-4-cyano-isoquinolines as novel, potent, and selective inhibitors of human 11β-hydroxydehydrogenase 1 (11β-HSD1)Shung C Wu, David Yoon, Janice Chin, et al.
Journal of Medicinal Chemistry|August 26, 2009
Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activityClaudio Mapelli, Sesha I Natarajan, Jean-Philippe Meyer, et al.
Journal of Medicinal Chemistry|May 25, 2017
Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 InhibitorXiang-Yang Ye, Stephanie Y Chen, Shung Wu, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
ACS Medicinal Chemistry Letters|July 23, 2014
Optimization of 1,2,4-Triazolopyridines as Inhibitors of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1)Jun Li, Lawrence J Kennedy, Haixia Wang, et al.
Bioorganic & Medicinal Chemistry Letters|February 13, 2007
Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulatorsLawrence G Hamann, Mark C Manfredi, Chongqing Sun, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2008
Pyridine amides as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1Haixia Wang, Zheming Ruan, James J Li, et al.
Journal of Medicinal Chemistry|April 9, 2009
N-aryl-oxazolidin-2-imine muscle selective androgen receptor modulators enhance potency through pharmacophore reorientationAlexandra A Nirschl, Yan Zou, Stanley R Krystek, et al.
Journal of Medicinal Chemistry|March 18, 2005
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activitiesPratik V Devasthale, Sean Chen, Yoon Jeon, et al.
ACS Medicinal Chemistry Letters|January 8, 2019
Discovery of Clinical Candidate BMS-823778 as an Inhibitor of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1)Jun Li, Lawrence J Kennedy, Steven J Walker, et al.
Bioorganic & Medicinal Chemistry Letters|October 11, 2011
Discovery of 3-hydroxy-4-cyano-isoquinolines as novel, potent, and selective inhibitors of human 11β-hydroxydehydrogenase 1 (11β-HSD1)Shung C Wu, David Yoon, Janice Chin, et al.
Journal of Medicinal Chemistry|August 26, 2009
Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activityClaudio Mapelli, Sesha I Natarajan, Jean-Philippe Meyer, et al.
Journal of Medicinal Chemistry|May 25, 2017
Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 InhibitorXiang-Yang Ye, Stephanie Y Chen, Shung Wu, et al.
Pageof 3